Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

VNQI trades at $45.54, up 0.89% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The ETF offers broad international real estate exposure with a low 0.12% expense ratio and a 4.6% dividend yield, though it has underperformed domestic peers in total returns over five years. Recent news highlights its role as a diversification tool amid stabilizing global rates.

The outlook is mixed: VNQI provides cost-effective global diversification and income, but faces headwinds from weaker international performance and currency risks. Investors seeking yield and non-U.S. exposure may find value, though near-term technical weakness and competitive pressure from domestic ETFs pose risks to momentum.